Welcome to our dedicated page for Liquidia SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Liquidia's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Liquidia's regulatory disclosures and financial reporting.
Serendipity Biopharma LLC files a Form 144 reporting proposed sales of 100,000 shares of common stock. The notice lists an aggregate intended sale price of $4,228,000.00 and an intended sale date of 05/08/2026. The excerpt shows multiple executed 10b5-1 sales from 04/09/2026 through 05/07/2026, including several 25,000-share transactions under a 10b5-1 plan.
Liquidia Corp Chief Executive Officer Roger Jeffs reported indirect open‑market sales of 75,000 shares of common stock over three days at volume-weighted average prices of $40.10, $40.78, and $42.09. The Form 4 shows these sales were effected by Serendipity BioPharma LLC, an entity for which Jeffs serves as manager with sole voting and dispositive power, under a Rule 10b5-1 trading plan adopted on November 5, 2025. After the transactions, Serendipity reports holding 1,348,095 Liquidia shares indirectly, a separate living trust reports holding 46,595 shares indirectly, and Jeffs directly holds 1,137,508 shares, while additional unvested RSU awards are also disclosed.
LQDA: An affiliate filed a Form 144 reporting proposed sales of 25,000 shares pursuant to resale notices.
The filing also lists multiple completed 10b5-1 sales by SERENDIPITY BIOPHARMA LLC and a sale by ROGER JEFFS on dates between 04/09/2026 and 05/06/2026, with individual trade proceeds shown for each transaction.
Liquidia Corp Chief Accounting Officer Dana Boyle reported an open-market sale of 1,576 shares of common stock at $37.78 per share. The transaction was executed under a pre-arranged Rule 10b5-1 plan adopted on December 15, 2023 and was made to cover taxes tied to the settlement of previously granted restricted stock units. After the sale, Boyle directly holds 175,342 shares, which include significant unvested RSU awards and shares acquired through the company’s employee stock purchase plan.
Liquidia Corp Chief Business Officer Jason Adair sold 688 shares of common stock. The open-market sale on April 27, 2026 was executed at $41.65 per share pursuant to a Rule 10b5-1 trading plan and was used to cover taxes from the settlement of restricted stock units. Following the transaction, Adair directly holds 214,738 shares, along with multiple grants of unvested RSUs and shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia Corporation uses its 2026 proxy to highlight a breakthrough year driven by the launch of YUTREPIA, which generated hundreds of millions in net product sales and carried the company to profitability within four months. The company ended the year with $190.7 million in cash and positive cash flow. Management describes a large opportunity in prostacyclin therapies, citing over $4.5 billion in branded sales across PAH and PH-ILD, with treprostinil formulations at about $2.9 billion and roughly 60,000 addressable PH-ILD patients, most still untreated. Liquidia plans six new clinical studies in 2026 to strengthen YUTREPIA’s profile, advance its L606 inhaled treprostinil candidate into a pivotal Phase 3 RE-SPIRE study, and explore new indications. The proxy also asks stockholders to elect three Class II directors, ratify PricewaterhouseCoopers LLP as auditor, and approve an advisory vote on executive compensation at a fully virtual June 16, 2026 annual meeting.
Liquidia Corp Chief Executive Officer–associated entity sells shares under pre-planned plan. An entity managed by CEO Roger Jeffs, Serendipity BioPharma LLC, sold 18,839 shares of Liquidia common stock on April 17, 2026 at a volume-weighted average price of $40.6049 per share, with individual trades between $40.00 and $41.85.
After the sale, Serendipity BioPharma LLC held 1,423,095 shares indirectly for Jeffs, while he also held 1,137,599 shares directly and 46,595 shares through a living trust. Footnotes state the trade was effected under a Rule 10b5-1 trading plan adopted on November 5, 2025, and Jeffs also has several tranches of unvested restricted stock units.
Serendipity Biopharma (LQDA) reported multiple Form 144 sale notifications showing controlled sales of common stock by related parties. The excerpt lists scheduled 10b5-1 sales and an individual sale, including 25,000 shares on 04/16/2026 for $1,007,800 and 32,744 shares on 04/13/2026 for $1,256,387.28. The filings identify 10b5-1 plan activity and a sale attributed to Roger Jeffs; timing and plan mechanics are shown by sale dates in April 2026.
Liquidia Corp Chief Executive Officer Roger Jeffs reported open-market sales of company common stock through entities he controls. On April 16 he sold 25,000 shares at an average price of $40.312, on April 15 another 25,000 shares at $40.1409, and on April 14 3,300 shares at $40.00, totaling 53,300 shares sold. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025. After these transactions, Jeffs’ indirect holdings were 1,441,934 shares, alongside 1,137,599 shares held directly and 46,595 shares held indirectly through Serendipity BioPharma LLC, plus substantial unvested restricted stock units.